Artiva Biotherapeutics Inc. (ARTV)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Artiva Biotherapeutics: 'Buy' On AlloNK POC And FDA Phase 3 Alignment For Refractory RA
Artiva Biotherapeutics (ARTV) is maintained as a "Buy," driven by FDA alignment for a single phase 3 trial of AlloNK plus rituximab in refractory RA. Company's AlloNK plus rituximab demonstrated strong ACR50 response rates in early studies, with phase 3 initiation targeted for 2H 2026 and data expected in 2H 2028. The company addresses a significant unmet need in 3rd-line RA, targeting 150K–200K U.S. patients unresponsive to prior biologics, with a $5 billion spend on this population.
Artiva Biotherapeutics: Upcoming Data Presentations May Bring Them Out Of Being Ignored
Artiva Biotherapeutics is working on NK cell-based immunotherapy to treat autoimmune disease. Their lead project is an unmodified, preserved NK product that seeks to address challenges posed for CAR T-cell therapies. Early trial data in B-cell lymphoma suggests activity, and ARTV is guiding a data readout in the near term for autoimmune disease.
This Biotech IPO Stock Aims to Seize a Multibillion-Dollar Market with Its Innovative Treatment
Artiva has two-bagger potential in the eyes of multiple Wall Street analysts. Its cell therapies could provide a much more efficient treatment of autoimmune diseases.
Artiva Biotherapeutics' Investigational Scalable Cell Therapies For Autoimmune Disorders, Analyst Initiate With Bullish Pitch
In July, Artiva Biotherapeutics, Inc. ARTV priced its upsized initial public offering of 13.92 million shares at $12.00 per share, with gross proceeds of approximately $167.0 million.
Insider Buying in These 2 IPOs Is Huge, Plus Financial CEOs Pick Up Shares
24/7 Wall St. Insights In the past week or so, initial public offerings at a biotech and an investment management firm attracted huge insider buying.
